Arming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer
Date
2021
Authors
Hickey, T.E.
Dwyer, A.R.
Tilley, W.D.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
British Journal of Cancer, 2021; 125(12):1599-1601
Statement of Responsibility
Theresa E. Hickey, Amy R. Dwyer and Wayne D. Tilley
Conference Name
Abstract
Most breast cancers are driven by oncogenic activity of the estrogen receptor alpha (ER). Resistance to ER target therapies is the major cause of breast cancer death. Recently, there has been renewed interest in targeting the androgen receptor (AR) to treat ER-driven breast cancers. Herein, we discuss evidence for an AR agonist, not antagonist, treatment strategy.
School/Discipline
Dissertation Note
Provenance
Description
Published online: 22 July 2021
Access Status
Rights
© The Author(s), under exclusive licence to Springer Nature Limited 2021. Published on Behalf of CRUK